Illimis has completed a Series B funding round, securing $42m for the development of its GAIA-based Alzheimer's disease therapeutics.

Investigation Reveals Deep Flaws in FDA Drug Approval Process, Raising Concerns Over Public Safety** A recent investigative report has uncovered alarming findings regarding the ...

A groundbreaking study from the Centre for Addiction and Mental Health (CAMH) in Canada has revealed that an experimental ...

The three philanthropists devoted themselves and their resources to important causes during lifetimes of service to Palm Beach and beyond.

The new dosing schedule with a more gradual titration significantly lowered incidence of ARIA-E in the TRAILBLAZER-ALZ 6 trial.

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

Animal studies support that theory. GLP-1 drugs reduce inflammation in the brain and interfere with reward pathways linked to ...

Novo Nordisk's pipeline, especially the oral GLP-1 and Alzheimer’s trial, offers significant long-term upside. Click here to ...

A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

A journey through the FDA’s newly released complete response letters gave glimpses into the journeys to market for Eli ...

The Food and Drug Administration (FDA) has updated the labeling for Kisunla ™ (donanemab-azbt) to include a new recommended titration dosing schedule for adults with early symptomatic Alzheimer ...

A commonly prescribed pain medication—gabapentin—often considered a safer alternative to opioids for those who suffer from low back pain is now under scrutiny after being linked to increased risks of ...